Ind-Swift Ltd. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Chandigarh, Chandigarh. The firm operates in both domestic and export markets. The company is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The firm is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. The company operates through various divisions, such as Herba Plus Division, Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Herba Plus Division is engaged in the manufacturing of ayurvedic and pharmaceutical products, such as general category formulations, beta lactam, steroids and hormones, cephalosporins, oncological, soft gelatin capsules, and herbal and nutraceuticals. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
18 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.